Drugs / Multi-epitope Folate Receptor Alpha Peptide Vaccine
Multi-epitope Folate Receptor Alpha Peptide Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01606241 | Jul 2012 → Sep 2014 | breast carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03012100 | Mar 2017 → Feb 2025 overdue | bilateral breast carcinoma, inflammatory breast carcinoma, triple-negative breast carcinoma | Academic and Community Cancer Research United | Active not recruiting | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multi-epitope Folate Receptor Alpha Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01606241 ↗ |
| Modality | Vaccine | “peptide-based vaccine” NCT01606241 ↗ |
| Route | Other | “multi-epitope folate receptor alpha peptide vaccine intradermally (ID)” NCT01606241 ↗ |